SecBot SecBot
8-K ·Filed Jul 8, 2026

AZTA

Azenta, Inc.
MIXED
Impact 5/10
Horizonweeks Processed4mo ago SEC0001628280-26-047591
8-K material event: Items 1.01, 2.01
Actionable Insight ◆ Mixed

The $35M vendor loan matures October 1, 2026. Monitor Thelema's ability to secure third-party refinancing, a default risk could turn this into a collection event. The divestiture simplifies Azenta's portfolio; with ~$400M in pro forma cash/securities, watch for M&A or share buyback announcements. Earnings impact is muted since B Medical was already classified as discontinued operations.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.51
T+0 close · Jul 8, 2026 · via day close
Latest settled
+42.35%
T+60 · $34.89
Vs SPY
+40.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $24.51entry
  2. T+1 · 4mo ago +3.71%α +2.87% · $25.42
  3. T+5 · 4mo ago +3.79%α +2.93% · $25.44
  4. T+20 · 3mo ago +29.82%α +26.55% · $31.82
  5. T+60 · 7w ago +42.35%α +40.04% · $34.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Azenta completed the sale of B Medical Systems to Thelema for $63M total consideration, consisting of $28M cash received and a $35M vendor loan secured by a first-priority pledge over B Medical's equity. The vendor loan carries 6.0% interest, matures in three months (October 1, 2026), and is classified as a related-party transaction since Thelema is majority-owned by Luc Provost, a VP of Azenta. The divestiture aligns with Azenta's strategy to focus on core life sciences, but the large vendor loan receivable ($35M) creates near-term credit risk and tied-up capital.

Key Financial Metrics

Deal Value
$63.0M
Deal Type
acquisition

Key Facts

  • Sale of B Medical Systems completed July 1, 2026 for fixed $63M total consideration.
  • $28M cash received ($9M deposit from Dec 2025 + $19M at closing); $35M funded via secured vendor loan at 6.0% p.a., maturing in 3 months.
  • Thelema, the buyer, is majority-owned by Luc Provost (Azenta VP and CEO of B Medical); Audit Committee approved the related-party transaction.
  • Pro forma balance sheet shows cash increases by ~$19M to $253M, a $35M short-term note receivable, and a $41.5M reduction in retained earnings (cumulative translation + costs to sell).
  • B Medical was already classified as a discontinued operation; the 8-K confirms no adjustment to previously estimated loss on disposal.

Financial Impact

Azenta receives $28M net cash proceeds and holds a $35M secured 3-month vendor loan. Retained earnings reduced by ~$41.5M (cumulative translation of $46.9M offset by $5.4M estimated cost to sell). Pro forma cash and marketable securities total ~$399.5M.

cashretained_earningsnote_receivableassets_disposed

Risk Factors

  • Thelema may fail to refinance the $35M vendor loan by October 1, 2026, creating a default and potential asset impairment or enforcement action.
  • Related-party nature (buyer owned by Azenta VP) increases governance scrutiny and potential reputational risk.
  • Cash position appears strong post-deal, but Azenta has not announced specific capital allocation plans, no buyback or M&A guidance provided.

Market Snapshot

Exchange
Nasdaq
Sector
Special Industry Machinery, NEC
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-047591
Exhibit: exhibit102-xexxazentaxthel.htm0001628280-26-047591
Exhibit: exhibit992-xunauditedprofo.htm0001628280-26-047591
Exhibit: exhibit22-xexxazentaxthele.htm0001628280-26-047591
Exhibit: exhibit991-xazentapressrel.htm0001628280-26-047591
Document: azta-20260701.htm0001628280-26-047591
Document: 0001628280-26-047591-index-headers.html0001628280-26-047591
Document: 0001628280-26-047591-index.html0001628280-26-047591
Document: 0001628280-26-047591.txt0001628280-26-047591

Track record

12 reports on AZTA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +29.70% at T+60 after the Aug 4, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Bullish 6/10 Entry $48.90 Now $47.22 −3.44% settles Nov 18
  2. Oct 30, 202617d ago 8-K Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
  3. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
  4. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $35.89 to $37.18 Now $47.22 −31.57% ▼ −3.59% −4.57% vs SPY
  5. Sep 17, 20268w ago 8-K Neutral 2/10 Entry $33.63 to $34.20 Now $47.22 +40.41% ▲ +1.69% +1.09% vs SPY
  6. Sep 4, 202610w ago 8-K Neutral 4/10 Entry $31.33 to $32.04 Now $47.22 +50.72% ▲ +2.27% +3.48% vs SPY
  7. Aug 24, 202612w ago 8-K Neutral 4/10 Entry $32.88 to $32.65 Now $47.22 +43.61% ▼ −0.70% −1.17% vs SPY
  8. Aug 8, 202614w ago Institutional Cluster Mixed 5/10 Entry $33.33 to $33.58 Now $47.22 +41.67% ▲ +0.75% +0.80% vs SPY
  9. Aug 4, 202614w ago Press Release Bullish 7/10 Entry $31.82 to $33.53 Now $47.22 +48.40% ▲ +5.37% +5.02% vs SPY
  10. Jul 8, 202618w ago 8-K Mixed 5/10 Viewing Entry $24.51 to $25.44 Now $47.22 +92.66% ▲ +3.79% +2.93% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026